Alkermes plc (ALKS)

24,44 -0,21 (-0,85%) Al cierre: 04:00PM EDT

Alkermes plc

Connaught House
1 Burlington Road Dublin 4
Dublin D04 C5Y6
Ireland
353 1 772 8000
https://www.alkermes.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 2100

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Richard F. Pops	Chairman & CEO	2,61M	N/A	1962
Mr. Blair C. Jackson	Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO	1,17M	N/A	1973
Mr. David Joseph Gaffin	Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary	1,15M	N/A	1972
Mr. Iain Michael Brown	Senior VP & CFO (Leave of Absence)	950,88k	N/A	1969
Dr. Craig C. Hopkinson M.D.	Executive VP of Research & Development and Chief Medical Officer	1,24M	N/A	1968
Dr. Floyd E. Bloom M.D.	Founder	57,73k	N/A	1937
Mr. Samuel J. Parisi	Interim Principal Accounting Officer & VP of Finance	N/A	N/A	1975
Mr. Thomas Harvey	Chief Information Officer & Senior VP of IT	N/A	N/A	N/A
Ms. Sandra Coombs	Senior Vice President of Corporate Affairs & Investor Relations	N/A	N/A	N/A
Mr. Stephen Schiavo	Senior Vice President of Human Resources	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Gobierno corporativo

El ISS Governance QualityScore de Alkermes plc, a día 1 de abril de 2024, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 3; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.